As
mentioned earlier, piracetam oldest nootrop and most studied. It is used both
in pure form and restructured. For more information on the modernization of the
nootropa and will be discussed.
The history
of clinical use of piracetam has nearly four decades. He first appeared on the
market in 1972 under the name "Nootropil®" as a drug for the
treatment of memory and balance issued by the Belgian company UCB Pharma.
Currently,
there are more than 10 "piratsetamopodobnyh" drugs, including
piracetam itself, which are used in different countries or are in some stage of
clinical trials. These include:
•
piracetam, levetiracetam, and seletratsetam brivaratsetam (developed by UCB
Pharma, Belgium);
•
oxiracetam (developed by ISF, Italy);
•
aniracetam (developed by Roche Pharmaceuticals, Switzerland);
•
pramiracetam (developed by Warner-Lambert, USA) [6];
•
fenilpiratsetam (developed at the Institute of Biomedical Problems, RAMS,
manufactured by Valenta Pharmaceuticals, Russia).
All these
drugs have a similar chemical structure with piracetam, the main component of
which is a pyrrolidone ring, in connection with which this group was named
"racetam." Nesmot¬rya on sectors Structural similarities, the
clinical effects observed with racetam quite diverse and allow to divide them
into three groups:
1. Drugs
primarily used for the treatment of cognitive disorders. This subgroup includes
piracetam, pramiracetam, fenilpiratsetam, oxiracetam and aniracetam (the latter
two drugs in clinical practice is not used). It should be noted that this group
of drugs may also be used in violation of the balance, and cortical myoclonus
dyslexia.
2.
Preparations for the treatment of epilepsy. This subgroup consists of
levetiracetam, and brivaratsetam seletratsetam. The impact of these drugs on
cognitive function is unclear.
3. The
third subgroup combines the drugs clinical efficacy is unknown. These are drugs
like nefiratsetam (for which it was not possible to prove effective in
improving cognitive functions in stroke patients) and rolipram (currently
studied as an antidepressant). This subgroup includes several other drugs that
are in clinical studies.
As a
conclusion, we can say that a person is interested in developing their own
intellectual capabilities, you should pay attention to the first group of
nootropics. The material is intended for more detailed information on piracetam.
I'd add that the effect of the use of present and very positive. More about
nootropics - in future releases.
0 comments:
Post a Comment